NEW YORK (GenomeWeb) – Molecular diagnostics firm Rosetta Genomics reported today a 10 percent drop in third quarter revenues amid lower sales of its urologic and solid tumor testing services.

For the three months ended Sept. 30, Rosetta's revenues declined to $2.2 million from $2.4 million in the same period last year. Sales of its urologic cancer testing services fell 25 percent to $970,000 from $1.3 million, while revenues from solid tumor testing services fell 24 percent to $841,000 from $1.1 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Germany's Project DEAL has come to an agreement with the publisher Wiley over journal access and open-access publishing, ScienceInsider reports.

Researchers uncover additional loci associated with lifespan, which the Telegraph says could be folded into a genetic test.

A Canadian panel recommends public coverage of the gene therapy Kymriah if its cost comes down, the Globe and Mail reports.

In Nucleic Acids Research this week: new accurate quantification by sequencing approach, CNV breakpoints in Plasmodium falciparum, and more.

Sponsored by
Loop Genomics

This webinar will provide a comparison of several next-generation sequencing (NGS) approaches — including short-read 16S, whole-genome sequencing (WGS), and synthetic long-read sequencing technology — for use in microbiome research studies.

Sponsored by
L7 Informatics

This webinar will provide a first-hand look at how Gradalis, a clinical-stage immunotherapy developer, is using an information management solution from L7 to streamline its research, clinical, and manufacturing operations.